Table 1. Baseline demographic data by baseline FGF23 value.
| Patients with baseline FGF23 in the lower half of values (<759 RU/ml) (n=22) |
Patients with baseline FGF23 in the upper half of values (>759 RU/ml) (n=22) |
|
|---|---|---|
|
| ||
| Gender (M/F %) | 52/48 | 38/62 |
|
| ||
| Age (years) | 15.5 ± 2.8 | 17.4 ± 2.8 |
|
| ||
| Time on dialysis (months) | 24.1 ± 34.7 | 23.4 ± 16.4 |
|
| ||
| Race (%) | ||
| Caucasian | 29 | 48 |
| Hispanic | 52 | 52 |
| African American | 14 | |
| Asian | 5 | |
|
| ||
| Steroid immunosuppression (%) | 29 | 33 |
|
| ||
| Residual urine (%) | 52 | 42 |
|
| ||
| ESRD etiology (%) | ||
| Dysplasia/reflux | 48 | 24 |
| Glomerulonephritis | 29 | 29 |
| Genetic disease | 19 | |
| Unknown | 24 | 29 |
|
| ||
| Donor type | ||
| Living related | 24 | 38 |
| Deceased donor | 76 | 62 |
|
| ||
| Phosphate supplementation on post- operative day 5 |
||
| Percentage receiving (%) | 33 | 43 |
| Amount received | ||
| Mean ± SD (mg) | 350 ± 586 | 400 ± 586 |
| Median (mg) (IQ range) | 0 (0,500) | 0 (0,750) |
FGF23, fibroblast growth factor 23; ESRD, end stage renal disease